WO2005089918A1 - ポリスルホン系選択透過性中空糸膜束及びその製造方法 - Google Patents
ポリスルホン系選択透過性中空糸膜束及びその製造方法 Download PDFInfo
- Publication number
- WO2005089918A1 WO2005089918A1 PCT/JP2005/005140 JP2005005140W WO2005089918A1 WO 2005089918 A1 WO2005089918 A1 WO 2005089918A1 JP 2005005140 W JP2005005140 W JP 2005005140W WO 2005089918 A1 WO2005089918 A1 WO 2005089918A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hollow fiber
- fiber membrane
- membrane bundle
- polysulfone
- less
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 362
- 239000012510 hollow fiber Substances 0.000 title claims abstract description 334
- 238000000034 method Methods 0.000 title claims abstract description 84
- 230000008569 process Effects 0.000 title claims abstract description 9
- 210000004369 blood Anatomy 0.000 claims abstract description 95
- 239000008280 blood Substances 0.000 claims abstract description 95
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 215
- 238000001035 drying Methods 0.000 claims description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 85
- 238000010828 elution Methods 0.000 claims description 56
- 229920002492 poly(sulfone) Polymers 0.000 claims description 56
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 53
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 53
- 230000002829 reductive effect Effects 0.000 claims description 51
- 238000004519 manufacturing process Methods 0.000 claims description 47
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 47
- 238000009987 spinning Methods 0.000 claims description 31
- 238000002835 absorbance Methods 0.000 claims description 30
- 238000004090 dissolution Methods 0.000 claims description 30
- 238000004898 kneading Methods 0.000 claims description 30
- 238000012360 testing method Methods 0.000 claims description 29
- 210000003734 kidney Anatomy 0.000 claims description 27
- 238000003756 stirring Methods 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 23
- 229920001007 Nylon 4 Polymers 0.000 claims description 20
- 229920000642 polymer Polymers 0.000 claims description 18
- 238000000502 dialysis Methods 0.000 claims description 16
- 230000007423 decrease Effects 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 10
- 230000001678 irradiating effect Effects 0.000 claims description 9
- 238000007922 dissolution test Methods 0.000 claims description 7
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 6
- 239000000243 solution Substances 0.000 description 54
- 238000003860 storage Methods 0.000 description 33
- 238000004132 cross linking Methods 0.000 description 30
- 238000006731 degradation reaction Methods 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 239000002994 raw material Substances 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 20
- 230000015556 catabolic process Effects 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 238000005406 washing Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- 230000035699 permeability Effects 0.000 description 17
- 230000006837 decompression Effects 0.000 description 15
- 230000006866 deterioration Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000005345 coagulation Methods 0.000 description 14
- 230000015271 coagulation Effects 0.000 description 14
- 230000007547 defect Effects 0.000 description 14
- 239000011148 porous material Substances 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 13
- 239000011261 inert gas Substances 0.000 description 13
- 230000009467 reduction Effects 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 238000005259 measurement Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 230000001590 oxidative effect Effects 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229920001477 hydrophilic polymer Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000009423 ventilation Methods 0.000 description 6
- -1 vinyl lidone Chemical compound 0.000 description 6
- 239000004695 Polyether sulfone Substances 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 231100000987 absorbed dose Toxicity 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000005251 gamma ray Effects 0.000 description 5
- 229920006393 polyether sulfone Polymers 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101001012040 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Immunomodulating metalloprotease Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 3
- 230000001112 coagulating effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000010894 electron beam technology Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 238000010525 oxidative degradation reaction Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 238000004804 winding Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229940123973 Oxygen scavenger Drugs 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- PSMHZKZVTXCVKA-UHFFFAOYSA-N 2-(pyridin-2-yldiazenyl)benzene-1,3-diol Chemical compound Oc1cccc(O)c1N=Nc1ccccn1 PSMHZKZVTXCVKA-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DKNPRRRKHAEUMW-UHFFFAOYSA-N Iodine aqueous Chemical compound [K+].I[I-]I DKNPRRRKHAEUMW-UHFFFAOYSA-N 0.000 description 1
- GQWNECFJGBQMBO-UHFFFAOYSA-N Molindone hydrochloride Chemical compound Cl.O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 GQWNECFJGBQMBO-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229910010066 TiC14 Inorganic materials 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000003303 reheating Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
- B01D67/0009—Organic membrane manufacture by phase separation, sol-gel transition, evaporation or solvent quenching
- B01D67/0011—Casting solutions therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
- B01D67/0009—Organic membrane manufacture by phase separation, sol-gel transition, evaporation or solvent quenching
- B01D67/0016—Coagulation
- B01D67/00165—Composition of the coagulation baths
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/009—After-treatment of organic or inorganic membranes with wave-energy, particle-radiation or plasma
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/0093—Chemical modification
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/0095—Drying
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/66—Polymers having sulfur in the main chain, with or without nitrogen, oxygen or carbon only
- B01D71/68—Polysulfones; Polyethersulfones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2323/00—Details relating to membrane preparation
- B01D2323/30—Cross-linking
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2323/00—Details relating to membrane preparation
- B01D2323/34—Use of radiation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/28—Degradation or stability over time
Definitions
- the present invention relates to a polysulfone-based selectively permeable hollow fiber membrane bundle which is particularly suitable for use in blood purifiers and the like, in which safety and performance stability are high, a method for producing the same, and a blood purifier.
- cellulose which is a natural material, and derivatives thereof such as cellulose diacetate, cellulose triacetate, and synthetic polymers are used.
- Modules such as hemodialyzers, hemofilters, and hemodiafiltration filters that use dialysis membranes or ultrafiltration membranes using polymers such as polysulfone, polymethylmethacrylate, and polyacrylonitrile as separation materials are widely used. ing. Modules using hollow fiber membranes as separation materials are particularly important in the field of dialysis machines due to their advantages such as reduced extracorporeal blood volume, high efficiency in removing blood substances, and productivity during module production. But high ,.
- a polysulfone-based resin having high water permeability has attracted attention as the one most suited to the progress of dialysis technology.
- a semi-permeable membrane is made of polysulfone alone, since the polysulfone resin is hydrophobic, it causes an air-opening phenomenon with poor affinity for blood. Cannot be used.
- a method for solving the above-mentioned problem a method has been proposed in which a hydrophilic polymer is mixed with a polysulfone-based resin to form a film, thereby imparting hydrophilicity to the film.
- a method of blending a polyhydric alcohol such as polyethylene glycol has been disclosed (for example, see Patent Documents 1 and 2).
- Patent Document 1 JP-A-61-232632
- Patent Document 2 JP-A-58-114702 [0005] Also, a method of blending polyvinylpyrrolidone is disclosed (see, for example, Patent Documents 3 and 4).
- Patent Document 3 Japanese Patent Publication No. 5-54373
- Patent Document 4 Japanese Patent Publication No. 6-75667
- the latter method using polybutylpyrrolidone has attracted attention from the viewpoint of safety and economy, and the above-mentioned problem is solved by the method.
- the technology for imparting hydrophilicity by blending polybulpyrrolidone there is a problem that polybulpyrrolidone is eluted during dialysis and mixed into purified blood. If the amount of polybulpyrrolidone eluted is large, the accumulation of polybulpyrrolidone, which is a foreign substance to the human body, during long-term dialysis increases, which may cause side effects and complications. Therefore, the amount of polyvinylpyrrolidone eluted is determined by the dialysis-type artificial kidney device manufacturing approval standard. According to the standard, the amount of polybutylpyrrolidone eluted is determined by UV absorbance.
- Patent Document 5 Patent No. 3314861
- Patent Document 6 JP-A-6-165926
- Patent Document 7 JP-A-2000-350926
- Patent Document 8 discloses a semipermeable membrane for blood treatment in which the amount of the hydrophilic polymer eluted from the semipermeable membrane is 10 ppm or less.
- the document discloses a method for suppressing elution of the hydrophilic polymer from the semipermeable membrane for blood treatment, but is concerned with the degradation and decomposition of the hydrophilic polymer over time, which extends to the storage of the hollow fiber membrane. No mention is made of the effects of hydrogen peroxide.
- Patent Document 8 JP 2001-170171 A
- Patent Documents 9-119 also show that polyvinylylpyrrolidone elution from the membrane was suppressed. However, no consideration is given to the storage stability of the selective separation membrane as in the above patent document.
- Patent Document 9 JP-A-6-339620
- Patent Document 10 Japanese Patent Application Laid-Open No. 9-70524
- Patent Document 11 JP-A-9-70525
- Patent Document 12 JP-A-9-70526
- Patent Document 13 JP-A-9-103664
- Patent Document 14 Japanese Patent Application Laid-Open No. 10-66864
- Patent Document 15 JP-A-10-230148
- Patent Document 16 JP 2001-170167 A
- Patent Document 17 Japanese Patent Application Laid-Open No. 2003-201383
- Patent Document 18 JP-A-2003-245526
- Patent Document 19 Patent No. 3474205
- Patent Document 17 JP 2003-175320 A
- Patent Document 18 JP 2003-175321 A
- Patent Document 19 JP 2003-175322 A
- Patent Document 20 JP 2003-175320 A
- Patent Document 21 JP 2003-175321 A
- Patent Document 22 JP-A-2003-175322 Disclosure of the invention
- the present inventors have studied in detail the dissolution behavior of the polypyrrolidone, and as a result, the eluate eluted by the test method specified by the above-mentioned dialysis-type artificial kidney device manufacturing approval standard contains: It has been found that hydrogen peroxide, which cannot be measured by conventionally known UV absorbance, is contained. When hydrogen peroxide is present in the blood purifier and the permselective separation membrane, for example, it promotes the oxidative degradation of polyvinylpyrrolidone and increases the amount of polyvinylpyrrolidone eluted when the hollow fiber membrane bundle is preserved, resulting in storage stability. Found that sex is worse
- the present invention provides a polysulfone-based selectively permeable hollow fiber membrane bundle suitable for use in a blood purifier having high water permeability and used for the treatment of chronic renal failure, which is highly safe and stable in performance, and a method for producing the same. And to provide a blood purifier having high long-term storage stability.
- the present invention relates to a polysulfone-based selectively permeable hollow fiber membrane bundle containing polybulpyrrolidone, which is subjected to an elution test defined by the dialysis-type artificial kidney device manufacturing approval standard, and is used as the hollow fiber membrane bundle.
- the present invention relates to a polysulfone-based permselective hollow fiber membrane bundle having an elution amount of hydrogen peroxide of 5 ppm or less from water.
- the present invention divides the hollow fiber membrane bundle into ten pieces in the longitudinal direction
- the present invention relates to the above-mentioned polysulfone-based selectively permeable hollow fiber membrane bundle, in which the concentration of hydrogen peroxide in all the eluates is 5 ppm or less when an elution test prescribed by the kidney device manufacturing approval standard is performed.
- the present invention provides the polysulfone-based selective permeation wherein the amount of polybulpyrrolidone eluted from the hollow fiber membrane bundle is 10 ppm or less when an elution test specified by the dialysis type artificial kidney device manufacturing approval standard is performed.
- the present invention relates to a hollow fiber membrane bundle.
- the present invention provides a method for producing a polysulfone-based selectively permeable hollow fiber membrane bundle, comprising a process of spinning a solution containing a polysulfone-based polymer, polybulpyrrolidone, and a solvent, and further comprising:
- the method relates to a method in which the content of hydrogen peroxide is 300 ppm or less.
- the polysulfone-based selectively permeable hollow fiber membrane bundle of the present invention has a reduced amount of hydrogen peroxide eluted, and the hollow fiber membrane bundle caused by the hydrogen peroxide is stored for a long period of time. Deterioration of polybielpyrrolidone and the like is suppressed. Therefore, even after long-term storage, it is possible to maintain the maximum value of UV (220 to 350 nm) absorbance, which is the standard for the production of dialysis-type artificial kidney devices, at 0.10 or less. For this reason, the polysulfone-based selectively permeable hollow fiber membrane bundle of the present invention is suitable and suitable for a blood purifier having high water permeability and used for treatment of chronic renal failure.
- the above-described hollow fiber membrane bundle can be economically and stably produced by the production method of the present invention.
- the amount of hydrogen peroxide eluted from the filled polysulfone-based selectively permeable hollow fiber membrane bundle is suppressed, and the blood purifier caused by the hydrogen peroxide can be used for a long time.
- the blood purifier caused by the hydrogen peroxide can be used for a long time.
- deterioration of polyvinylpyrrolidone and the like in the polysulfone-based selectively permeable hollow fiber membrane bundle is suppressed. Therefore, even after long-term storage, it was possible to maintain the maximum value of UV (220-350 nm) absorbance, which is the approval standard for dialysis-type artificial kidney devices, at 0.10 or less, and the blood purifier was stored for a long time. In this case, safety can be ensured.
- FIG. 1 is a schematic diagram showing the amount of hydrogen peroxide eluted at each site when a hollow fiber membrane is divided into ten equal parts.
- FIG. 2 is a schematic diagram showing the degree of quality variation in a hollow fiber membrane bundle.
- the hollow fiber membrane bundle of the present invention is made of a polysulfone-based resin containing polybutylpyrrolidone.
- the polysulfone-based resin in the present invention is a general term for resins having a sulfone bond, and is not particularly limited.
- a polysulfone resin or a polyether sulfone resin having a repeating unit represented by the following formula is widely commercially available as a polysulfone-based resin, and is preferred because it is easily available.
- the polybierpyrrolidone used in the present invention is a water-soluble polymer compound obtained by biel polymerization of N_bierpyrrolidone, and is, for example, “Rubitec” from BASF, “Plasdon” from ISP, Daiichi Kogyo It is marketed by pharmaceutical companies under the brand name "Pitzcol", and there are products with various molecular weights.
- Rubitec from BASF
- Plasdon from ISP
- Daiichi Kogyo Daiichi Kogyo It is marketed by pharmaceutical companies under the brand name "Pitzcol”, and there are products with various molecular weights.
- a product having a single molecular weight may be used, or a mixture of two or more products having different molecular weights may be used.
- a commercially available product may be purified, for example, one having a sharp molecular weight distribution.
- the hollow fiber membrane bundle of the present invention has a hydrogen peroxide content of 300 ppm as polybutylpyrrolidone. Preferably manufactured using the following: 250 ppm or less is more preferred 200 ppm or less is even more preferred 150 ppm or less is even more preferred. If the content of hydrogen peroxide in the polyvinylpyrrolidone used as a raw material is 300 ppm or less, the amount of hydrogen peroxide eluted in the hollow fiber membrane bundle after film formation can be easily stabilized at 5 ppm or less, and the hollow fiber membrane can be easily stabilized. It is preferable because the quality of the bundle can be stabilized.
- reducing the hydrogen peroxide content to 300 ppm or less may be the first means for suppressing the oxidative deterioration of polypyrrolidone in the process of producing the selectively permeable hollow fiber membrane bundle.
- the method for producing the selectively permeable hollow fiber membrane bundle of the present invention is not limited at all, and for example, it can be preferably produced by a method known in JP-A-2000-300663.
- a method known in JP-A-2000-300663 16 parts by mass of polyether sulfone (4800P, manufactured by Sumitomo Chemical Co., Ltd.), 5 parts by mass of polybutylpyrrolidone (K_90, manufactured by BASF), 74 parts by mass of dimethylacetamide, and 5 parts by mass of water disclosed in the patent document Using a 50% aqueous solution of dimethylacetamide as the core solution, discharge it from the outside and inside of the double tube orifice at the same time, and pass it through the 50 cm idle section.
- the composition ratio of polybulpyrrolidone to the polysulfone-based polymer in the membrane may be within a range that can impart sufficient hydrophilicity and a high water content to the hollow fiber membrane. It is preferable that the polysulfone polymer is 99 to 80% by mass and the polybierpyrrolidone is 112 to 20% by mass.
- the ratio of polybutylpyrrolidone to the polysulfone-based polymer is more preferably 1.5% by mass or more, more preferably 2.0% by mass or more, and even more preferably 2.5% by mass or more.
- the ratio is too high, the effect of imparting hydrophilicity is saturated, and the amount of polyvinylpyrrolidone and Z or oxidatively degraded substances eluted from the film increases. Amount may exceed 10 ppm. Therefore, the content is more preferably 18% by mass or less, further preferably 15% by mass or less, still more preferably 13% by mass or less, and particularly preferably 10% by mass or less.
- the elution amount of hydrogen peroxide is preferably 5 ppm or less, and the elution amount of polyvinylpyrrolidone of the hollow fiber membrane bundle is preferably 10 ppm or less.
- the method for satisfying the above characteristics is not limited and may be any method.However, the method can be achieved by, for example, setting the composition ratio of polyvinylpyrrolidone to the polysulfone-based polymer in the above range, optimizing the film forming conditions of the hollow fiber membrane bundle, and the like. it can.
- the more preferred elution amount of polybierpyrrolidone is 8 ppm or less, more preferably 6 ppm or less, and even more preferably 4 ppm or less.
- the amount of the polyvinylpyrrolidone to be eluted is determined using an eluate eluted by a method according to the elution test method of the dialysis type artificial kidney device manufacturing approval standard. In other words, the hollow fiber membrane bundle force in the dry state is arbitrarily taken out. 1. Og is weighed, 100 ml of RO water is added thereto, and elution is performed at 70 ° C. for 1 hour to obtain an eluate.
- the amount is determined after the crosslinking treatment. Since the cross-linking treatment may be performed after the module is assembled, it is also possible to take out the hollow fiber membrane bundle from the assembled module and evaluate it.
- the polybulpyrrolidone is insolubilized by crosslinking.
- crosslinking method for example, Crosslinking with ⁇ -rays or electron beams is preferred because of the fact that no residue such as an initiator remains and material permeability is high, even among forces including crosslinking by ⁇ -rays or electron beams, thermal or chemical crosslinking, and the like.
- cross-linking is promoted by the coexistence of water. Therefore, it is a preferred embodiment that the cross-linking treatment is performed on the hollow fiber membrane bundle in a wet state.
- the crosslinking treatment can be performed either before the hollow fiber membrane bundle is incorporated into the blood purifier or after the hollow fiber membrane bundle is incorporated into the module.
- the insolubilization of polyvinylpyrrolidone by crosslinking in the present invention is determined by the solubility of dimethylformamide in the crosslinked membrane. That is, 10 g of the membrane after cross-linking is taken, a solution dissolved in 100 ml of dimethylformamide is separated by a centrifuge at 1500 rpm for 10 minutes, and the supernatant is removed. To the remaining insolubles, add again 100 ml of dimethylformamide, stir, and centrifuge under the same conditions to remove the supernatant. Again, add 100 ml of dimethylformamide, stir, perform the same centrifugation, and remove the supernatant. The remaining solid matter is evaporated to dryness, and its capacity and content of insoluble matter are determined.
- the content of the insoluble matter is preferably 0.5 to 40% by mass. One to 35% by mass is more preferable.
- first remove the filling liquid then flow pure water at 500 mL Zmin for 5 minutes in the eluate-side flow path, and then purify water in the blood-side flow path in the same manner. Flush at 200mLZmin for 5 minutes.
- pure water of 200 mL / min is passed through the membrane from the blood side to the dialysate side to complete the washing process.
- Medium than obtained module The empty fiber membrane bundle is taken out and freeze-dried to obtain a sample for measuring insoluble matter. The same washing process is performed for the hollow fiber membrane bundle module during drying to obtain a sample for measurement.
- the amount of polybutylpyrrolidone eluted, the amount of hydrogen peroxide eluted, and the dialysis-type artificial kidney device manufacturing approval standard are set. If the UV (220-350nm) absorbance is measured or misaligned, measure the sample in the same manner.
- the elution amount of hydrogen peroxide is preferably 5 ppm or less. 4 ppm or less is more preferred 3 ppm or less is still more preferred.
- the elution amount of the hydrogen peroxide exceeds 5 ppm, the storage stability deteriorates due to the oxidative deterioration of polyvinylpyrrolidone by the hydrogen peroxide as described above. Elution volume may increase. Regarding the storage stability, the most remarkable phenomenon is an increase in the amount of polybutylpyrrolidone eluted.
- the strength of the polyurethane adhesive used for module assembly is accelerated and the elution amount of degraded products such as urethane oligomers is increased. May lead to a decline.
- the increase in the amount of eluate due to deterioration caused by the oxidizing effect of hydrogen peroxide during long-term storage can be evaluated by measuring the UV (220-350 nm) absorbance set by the dialysis-type artificial kidney device manufacturing approval standard.
- the amount of hydrogen peroxide eluted is also determined using the eluate eluted by a method according to the elution test method of the dialysis type artificial kidney device manufacturing approval standard.
- the polysulfone-based selectively permeable hollow fiber membrane bundle is divided into 10 pieces in the longitudinal direction, and the amount of hydrogen peroxide eluted when measured for each is 5 ppm or less at all sites. Some are preferred embodiments. As described above, even if hydrogen peroxide is present at a specific site in the hollow fiber membrane bundle, the degradation reaction of the hollow fiber membrane bundle material starts from that location and propagates throughout the hollow fiber membrane bundle. It is necessary to ensure that the content in the longitudinal direction of the hollow fiber membrane bundle used as the module is equal to or less than a certain value over the entire region.
- the oxidative degradation of polyvinylpyrrolidone initiated by hydrogen peroxide at a specific site spreads throughout the hollow fiber membrane bundle in a chain, and the amount of hydrogen peroxide further increases due to the degradation.
- Pyrrolidone has a low molecular weight, so it is easy to elute from the bundle of hollow fiber membranes. Become. This degradation reaction proceeds in a chain. Therefore, when the hollow fiber membrane bundle is stored for a long period of time, the amount of hydrogen peroxide and polyvinylpyrrolidone eluted increases, which may lead to a decrease in safety when used for a blood purifier.
- the hollow fiber membrane bundle is divided into 10 pieces (substantially equally) in the longitudinal direction, and the amount of hydrogen peroxide eluted when measured for each is 3 ppm or less at all sites. Is a preferred embodiment.
- the permselective hollow fiber membrane bundle which is the first requirement of the present invention, is divided into 10 pieces in the longitudinal direction, and the elution of hydrogen peroxide when measured for each is 5 ppm or less at all sites. Can be achieved. More preferably, the elution of hydrogen peroxide is 2 ppm or less at all sites.
- the hollow fiber membrane bundle of the present invention is obtained by storing the hollow fiber membrane bundle at room temperature for one year and then performing a dissolution test specified by the dialysis-type human kidney device manufacturing approval standard.
- the maximum value of UV absorbance in the range of 220 to 350 nm is preferably 0.10 or less.
- the maximum value of the UV absorbance in the wavelength range of 220 to 350 nm is more preferably 0.08 or less.
- Such characteristics can be imparted by reducing the amount of hydrogen peroxide eluted to 5 ppm or less in all of the 10 longitudinally divided hollow fiber membrane bundles.
- the amount of hydrogen peroxide eluted within the above-mentioned regulated range for example, as described above, it is effective to set the amount of hydrogen peroxide in the polyvinylpyrrolidone used as a raw material to 300 ppm or less. It is.
- hydrogen peroxide is also generated during the production process of the hollow fiber membrane as described above, it is important to strictly control the production conditions of the hollow fiber membrane.
- the optimization of the drying conditions can be an effective means particularly for reducing the fluctuation of the elution amount in the longitudinal direction of the hollow fiber membrane.
- the step of dissolving the spinning solution for example, when stirring and dissolving a spinning solution containing a polysulfone-based polymer, polybutylpyrrolidone, and a solvent, a peracid is added to the polybulpyrrolidone. It was found that when hydrogen peroxide was included, the amount of hydrogen peroxide explosively increased due to the effect of oxygen in the melting tank and the effect of heating during melting. Therefore, when charging the raw material into the dissolving tank, it is preferable to input the raw material into the dissolving tank which has been replaced with an inert gas in advance. As the inert gas, nitrogen, argon and the like are preferably used. In some cases, a solvent and, in some cases, a non-solvent are added, but it is also a preferred embodiment to replace oxygen dissolved in these solvents and the non-solvent with an inert gas.
- the present inventors have tried to mix the raw materials at a low temperature in order to suppress the decomposition of polyvinylpyrrolidone. Even if it is a low-temperature melting, running costs are high under extreme conditions such that the temperature is below the freezing point. Therefore, usually 5 ° C or more and 70 ° C or less are preferable. 60 ° C or less Force is preferable. However, simply lowering the dissolution temperature will lead to degradation and degradation of polybutylpyrrolidone due to prolonged dissolution time, decrease in operability, and increase in equipment size, which is problematic for industrial implementation. .
- the polypyrrolidone when polyvinylpyrrolidone is to be dissolved at a low temperature, the polypyrrolidone becomes a sub-powder, which makes it difficult to dissolve the polyvinylpyrrolidone more and takes a long time for uniform dissolution.
- the present inventors have studied dissolution conditions for dissolving at low temperature in a short time. As a result, the present inventors have found that it is preferable to dissolve the components constituting the spinning solution after kneading them prior to dissolution, and have reached the present invention.
- components such as a polysulfone-based polymer, polyvinylpyrrolidone, and a solvent may be kneaded at a time, or polyvierpyrrolidone and a polysulfone-based polymer may be separately kneaded.
- the degradation of polybutylpyrrolidone is accelerated by contact with oxygen, generating hydrogen peroxide.
- a kneading line may be provided separately from the dissolving tank to perform the kneading, and the kneaded material in the next step may be supplied to the dissolving tank, or both the kneading and the dissolving may be performed in a dissolving tank having a kneading function. May be.
- the type and the type of the kneading device when the former is performed by a separate device are not limited. It can be either batch or continuous. It may be a static method such as a static mixer or a dynamic method such as a kneader / stirring kneader. The latter is preferred from the viewpoint of kneading efficiency.
- the kneading method may be any type such as a pin type, a screw type, and a stirrer type, which are not limited. Screw type is preferred. The shape and rotation speed of the screw may be appropriately selected from the balance between kneading efficiency and heat generation.
- the type of the dissolving tank in the case of using a dissolving tank having a kneading function is also not limited.
- planetary mixers and trimixes manufactured by Inoue Manufacturing Co., Ltd. correspond to this method.
- the ratio of the resin component such as polybutylpyrrolidone or polysulfone-based polymer to the solvent during kneading is not limited.
- the mass ratio of resin / solvent is preferably 0.1-3. 0.52 is more preferred.
- the present invention it is a technical point of the present invention to suppress the deterioration of polybutylpyrrolidone and perform efficient dissolution. Therefore, in a preferred embodiment, at least the system in which polypyrrolidone is present is kneaded and dissolved at a low temperature of 70 ° C. or lower under a nitrogen atmosphere. is there.
- the above method may be applied to a kneading line for the polysulfone polymer.
- the efficiency of kneading and dissolving and the generation of heat are two trade-offs. The selection of a device and conditions that avoid the trade-off as much as possible is an important element of the present invention. In that sense, the cooling method in the kneading mechanism is important and needs to be considered.
- the dissolution method is not limited.
- a dissolution method using a stirring-type dissolution apparatus can be applied.
- n is the blade rotation speed (rps)
- P density (KgZm 3 )
- ⁇ viscosity (Pa's)
- d stirring blade diameter ( m). If the Froude number is too large, the inertia force will increase, and the raw materials scattered in the tank will adhere to the walls and ceiling, and the desired film forming solution composition may not be obtained. Therefore, the Froude number is more preferably 1.25 or less, further preferably 1.2 or less, and still more preferably 1.15 or less.
- the number of fluids is more preferably 0.75 or more, and further preferably 0.8 or more.
- the stirring Reynolds number is more preferably 240 or less, further preferably 230 or less, and still more preferably 220 or less.
- the stirring Reynolds number is more preferable.
- the spinning solution since polybutylpyrrolidone tends to undergo oxidative decomposition under the influence of oxygen in the air, it is preferable to dissolve the spinning solution under an inert gas atmosphere.
- the inert gas include nitrogen and argon, and it is preferable to use nitrogen.
- the residual oxygen concentration in the dissolution tank is preferably 3% or less.
- the dissolution time can be shortened by increasing the nitrogen filling pressure, but the inert gas filling pressure is preferably at least atmospheric pressure and no more than 2 kgfZcm2 from the viewpoint of increasing equipment costs for forming a high pressure and work safety. Les ,.
- the stirring blade used in the present invention is a stirring blade having a shape used for dissolving a low-viscosity film-forming solution, such as a disk turbine type, a paddle type, a curved blade fan turbine type, or an arrow blade single-bin type.
- Forces include axial flow blades such as a radial flow blade, a propeller type, an inclined paddle type, and a Faudler type blade. The force is not particularly limited to these.
- the present inventors have adopted a combination involving the difficulties of preventing the oxidative deterioration of polypyrrolidone and improving the safety and productivity by reducing the amount of eluted substances from the hollow fiber membrane. By optimizing the drying conditions, the method is economically advantageous. It was found that the problem could be solved.
- the drying conditions of the drying method it is preferable to irradiate a 0.1 to 100 KW micro mouth wave under a reduced pressure of 20 KPa or less. Further, it is preferable that the frequency of the microwave is 1,000 to 5,000 MHz and the maximum temperature of the hollow fiber membrane bundle during the drying treatment is 90 ° C. or less.
- the use of decompression means that the drying of water is promoted by itself, which has the advantage of reducing the output of microphone mouth wave irradiation and shortening the irradiation time. Since it can be suppressed, the overall effect on the performance of the hollow fiber membrane bundle is small.
- drying with reduced pressure has the advantage that the drying temperature can be relatively lowered, and is particularly excellent in that the degradation and degradation of the hydrophilic polymer can be significantly suppressed. Therefore, the drying temperature is preferably 2080 ° C, more preferably 2060 ° C, still more preferably 2050 ° C, and even more preferably 30-45 ° C.
- the fact that decompression is involved means that decompression acts evenly on the central part and the outer peripheral part of the hollow fiber membrane bundle, the evaporation of water is promoted uniformly, and the hollow fiber membrane is dried uniformly. Therefore, it is possible to avoid the trouble of the hollow fiber membrane bundle caused by uneven drying.
- the heat generated by microwaves acts almost equally on the entire center and outer periphery of the hollow fiber membrane bundle, uniform heating and decompression work synergistically, resulting in a unique effect in drying the hollow fiber membrane bundle. obtain.
- the degree of decompression can be appropriately set according to the microwave output, the total water content of the hollow fiber membrane bundle, and the number of hollow fiber membrane bundles.
- the degree of reduced pressure is preferably 20 kPa or less, more preferably 15 kPa or less, and still more preferably 10 kPa or less. If the degree of decompression is high, not only the water evaporation efficiency decreases, but also the temperature of the polymer forming the hollow fiber membrane bundle increases, which may cause deterioration.
- a low degree of pressure reduction is preferable for suppressing the temperature rise and increasing the drying efficiency, but is preferably 0.1 lkPa or more because the cost required for maintaining the hermeticity of the apparatus increases. It is more preferably at least 0.25 kPa, even more preferably at least 0.4 kPa.
- the microwave output be high.
- the output is not increased so much as problems such as a decrease in wettability during use may occur.
- the hollow fiber membrane bundle is dried even at an output of less than 0.1kW. Drying is possible. Prolonged drying time can reduce throughput.
- the optimum value of the combination of the degree of decompression and the microwave output can be determined as appropriate according to the water content of the hollow fiber membrane bundle and the number of hollow fiber membrane bundles to be processed.
- the microwave output is more preferable than 0.180kW power, and 0.160kW is more preferable.
- the output of the microwave is determined, for example, by the total number of hollow fiber membranes and the total water content.
- a high-output microwave is suddenly irradiated, drying may be completed in a short time, but the hollow fiber membrane may be partially denatured and deformed like shrinkage.
- the hollow fiber membrane contains a water retention agent or the like, drying at high power or using microwaves can cause loss of the water retention agent due to scattering. In the past, there was no intention to irradiate microwaves under reduced pressure.
- the evaporation of the aqueous liquid becomes active even at a relatively low temperature, so that the degradation of polypyrrolidone and the deformation of the hollow fiber membrane due to high-power microwave and high temperature are caused.
- This has the dual effect of preventing damage to the hollow fiber membrane.
- drying with microwaves under reduced pressure is not limited to single-stage drying with a constant microwave output, but as another preferred embodiment, the output of a microphone mouth wave according to the progress of drying. So-called multi-stage drying. Therefore, the multistage drying will be described below.
- the multi-stage drying method can be an excellent method.
- the degree of pressure reduction, temperature, microwave output, and irradiation time may be determined in consideration of the total amount of hollow fiber membranes to be dried, an appropriate industrially acceptable drying time, and the like.
- the multi-stage drying can be performed in any number of stages, for example, 2 to 6 stages, but the industrially appropriate number of stages is 2 to 4 in consideration of productivity.
- the total amount of water contained in the hollow fiber membrane bundle is relatively large
- drying at a temperature of 90 ° C or less and under a reduced pressure of about 5 to 20 kPa for example, the first stage in the range of 30 to 100 kW, the second stage in the range of 10 to 30 kW, and the third stage
- the microwave irradiation time can be determined by tasting, such as 0.1-1 kW.
- the number of stages for reducing the output may be increased to, for example, 418 stages.
- the pressure reduction operation can be used in combination with microwave irradiation, it is advantageous in that drying can be performed even when the microwave output is relatively low.
- the first stage is about 10 100 minutes using a 10-20 kW microwave
- the second stage is about 3-10 kW for about 5-80 minutes
- the third is about 0.1-13 kW for about 1-60 minutes. May dry.
- the microwave output and irradiation time at each stage be reduced in conjunction with the reduction in the total amount of water contained in the hollow fiber membrane. This drying method is a very gentle drying method for the hollow fiber membrane bundle, and cannot be expected in the prior art of Patent Document 810 described above.
- the temperature is 80 ° C. or less, preferably 60 ° C. or less, under a reduced pressure of about 3 lOkPa.
- 0.1 to 0 Drying can be performed uniformly by adjusting the irradiation power and irradiation time of microwaves according to the degree of drying, such as irradiating microwaves of less than 5 kW for about 11 to 240 minutes.
- the degree of decompression can be set at a level of 0.1-20 kPa for each stage, and the degree of decompression at each stage is adjusted according to the situation, taking into account changes in the total water content and the water content of the hollow fiber membrane bundle. It can be set appropriately.
- the degree of decompression is reduced (for example, 0.1 to 5 kPa), and the microwave output is increased (for example, 10 to 30 kW).
- the operation of changing the degree of decompression in each stage may make the feature of the present invention even more significant when microwave irradiation is performed under reduced pressure.
- uniform irradiation and exhaust of microwaves in the microwave irradiation device It is also important to consider at all times.
- the drying method of irradiating microwaves under reduced pressure and the drying method of alternately reversing the ventilation direction may be used together, although the steps are complicated, but the present invention is not limited thereto. It is effective.
- the microwave irradiation method and the alternate ventilation reverse method each have advantages and disadvantages, and when high quality is required, these can be used in combination.
- alternate ventilation reverse method is adopted, and when the average water content advances to about 2060 mass%, it is possible to dry by irradiating microwaves under reduced pressure in the next stage.
- a drying method of alternately reversing the direction of ventilation after drying by irradiating microwaves may be used in combination.
- the method of combined use can be determined in consideration of the quality of the hollow fiber membrane obtained by drying, particularly the quality of a polysulfone-based selectively permeable hollow fiber membrane bundle having no partial fixation in the longitudinal direction of the hollow fiber membrane.
- drying methods can be performed at the same time, but are not practical due to disadvantages such as complexity and complexity of the equipment and soaring prices.
- an effective heating method such as far infrared rays may be used in combination.
- the maximum temperature of the hollow fiber membrane bundle during drying is determined by attaching an irreversible thermolabel to the side of the film that protects the hollow fiber membrane bundle, drying the film, removing it after drying, and checking the display. Can be measured by At this time, the maximum temperature of the hollow fiber membrane bundle during drying is preferably 90 ° C or less, more preferably 80 ° C or less. More preferably, it is 70 ° C or less. If the maximum temperature is high, the film structure is liable to change, which may cause performance degradation or oxidative degradation. In particular, in a hollow fiber membrane bundle containing polypyrrolidone, decomposition of polyvinylpyrrolidone by heat and the like is likely to occur, so it is important to prevent the temperature rise as much as possible.
- the drying temperature is preferably lower, it is preferably 30 ° C. or higher from the viewpoint of the cost of maintaining the degree of reduced pressure and shortening the drying time.
- the irradiation frequency of the microwave is preferably 1,000,000 5,000 MHz in consideration of the suppression of irradiation spots on the hollow fiber membrane bundle and the effect of extruding water in the pores from the pores. More preferably, it is 1,500 4, OOOMHz, and still more preferably, 2,000-3,000MHz.
- the hollow fiber membrane bundle In drying by the microwave irradiation, the hollow fiber membrane bundle is uniformly heated and dried. is important. In the above-mentioned microwave drying, non-uniform heating is caused by reflected waves generated at the time of microwave irradiation. Therefore, it is important to take measures to reduce non-uniform heating due to the reflected waves.
- the measure is not limited, for example, as disclosed in Japanese Patent Application Laid-Open No. 2000-340356, a method of providing a reflecting plate in an oven to reflect a reflected wave to make heating uniform is a preferred embodiment. Can be adopted.
- the hollow fiber membrane is preferably not completely dried. When dried out, the degradation of polypyrrolidone is accelerated and the production of hydrogen peroxide may increase significantly. In addition, there is a possibility that the wettability is reduced during re-wetting during use, and that the hollow fiber membrane is easily eluted because the polypyrrolidone is less likely to absorb water.
- the moisture content of the dried hollow fiber membrane is preferably 1% by mass or more, and is preferably less than the saturated moisture content. 1.5 mass% or more is more preferable. If the moisture content of the hollow fiber membrane is too high, bacteria can easily proliferate during storage, thread collapse may occur due to the weight of the hollow fiber membrane, and adhesive failure may occur during module assembly. There is. Therefore, the water content of the hollow fiber membrane is preferably 10% by mass or less, more preferably 7% by mass or less.
- the method of removing hydrogen peroxide mixed from the raw material polyvinylpyrrolidone or generated in the hollow fiber membrane bundle manufacturing process by washing also involves reducing the amount of hydrogen peroxide eluted from the hollow fiber membrane bundle. It is effective as a method to keep it at 5 ppm or less.
- an aqueous solution of 0 to 80% by mass of dimethylacetamide (DMAc) is preferable. More preferably, 15 to 70% by mass, still more preferably 25 to 60% by mass, even more preferably. Preferably, it is 30-50% by mass. If the concentration of the internal coagulation liquid is too low, the dense layer on the blood contact surface becomes thick, and solute permeability may decrease. If the concentration of the internal coagulation liquid is too high, the formation of a dense layer may be incomplete or the fractionation characteristics may be immediately deteriorated.
- the external coagulation liquid it is preferable to use a 50% by mass aqueous DMAc solution.
- the concentration of the external coagulating liquid is more preferably 40% by mass or less, further preferably 30% by mass or less, and still more preferably 25% by mass or less. If the concentration of the external coagulating liquid is too low, a large amount of water must be used to dilute the solvent brought in from the spinning solution, and the cost for waste liquid treatment increases. Therefore, the lower limit of the concentration of the external coagulating liquid is more preferably 5% by mass or more, further preferably 10% by mass or more, and still more preferably 15% by mass or more.
- the stretching is not substantially performed before the hollow fiber membrane structure is completely fixed.
- Substantially no drawing means that the film-forming solution discharged from the nozzle does not excessively loosen or tension, and for this purpose, for example, the roller speed during the spinning process is controlled.
- the ratio (draft ratio) of the discharge linear speed / the first opening speed of the coagulation bath (draft ratio) is preferably 0.7-7.1.8. If the draft ratio is low, the running hollow fiber membrane may be slackened, leading to a decrease in productivity. Therefore, a draft ratio of 0.8 or more is more preferable 0.9 or more is more preferable 0.95 or more is even more preferable.
- the membrane structure may be broken, for example, the dense layer of the hollow fiber membrane may be torn. Therefore, the draft ratio is more preferably 1.7 or less, further preferably 1.6 or less, still more preferably 1.5 or less, and particularly preferably 1.4 or less.
- the draft ratio is more preferably 1.7 or less, further preferably 1.6 or less, still more preferably 1.5 or less, and particularly preferably 1.4 or less.
- a hollow fiber membrane bundle is used as a means for reducing the amount of hydrogen peroxide eluted as described above or for setting the content of polybutylpyrrolidone on the outer surface of the hollow fiber membrane to a specific range.
- a washing step is introduced before the drying step. is important. For example, the hollow fiber membrane that has passed through the washing bath is completely wound up in a wet state.
- the obtained hollow fiber membrane is washed to remove excess solvent, polyvinylpyrrolidone.
- the hollow fiber membrane is washed by immersing the hollow fiber membrane in hot water at 70 to 130 ° C or an aqueous solution of 10 to 40 vol% ethanol or isopropanol at room temperature to 50 ° C. Is preferred.
- a preferred washing method is to arrange the hollow fiber membranes radially in a centrifugal washer and perform centrifugal washing for 30 minutes to 5 hours while spraying washing water at 40 ° C to 90 ° C in the form of a rotating force in a shower. is there.
- the above-mentioned cleaning methods may be performed in combination of two or more.
- the processing temperature is too low, it is necessary to increase the number of cleanings, which may lead to an increase in cost.
- the treatment temperature is too high, the decomposition of polybierpyrrolidone is accelerated, and conversely, the washing efficiency may decrease.
- the content of polyvinylpyrrolidone on the outer surface is optimized, and it is possible to suppress sticking and reduce the amount of eluted substances, and also to reduce the amount of hydrogen peroxide eluted.
- the blood purifier of the present invention is filled with the above-mentioned polysulfone-based selectively permeable hollow fiber membrane bundle.
- a blood purifier that is divided into 10 parts and the amount of hydrogen peroxide eluted when measured for each part is 5 ppm or less at all parts is suitable for the purpose of the present invention.
- the blood purifier is stored at room temperature for one year.
- the maximum value of UV absorbance in the wavelength range of 220 to 350 nm of the eluate was 0.10 or less.
- the maximum value of UV absorbance in the wavelength range of 220 to 350 nm is more preferably 0.08 or less.
- the blood purifier of the present invention can be imparted with properties to be provided by modularizing it using the above-described polysulfone-based selectively permeable hollow fiber membrane bundle. Therefore, in the polysulfone-based selectively permeable hollow fiber membrane bundle filled in the blood purifier of the present invention, the elution amount of hydrogen peroxide is more preferably 4 ppm or less, more preferably 3 ppm or less. It is a preferred embodiment to have the preferred characteristics that the lysulfone-based selectively permeable hollow fiber membrane bundle should have. In addition, the polysulfone-based selectively permeable hollow fiber membrane bundle used in the present invention can be stably and economically manufactured by the above-described manufacturing method.
- the burst pressure of the hollow fiber membrane bundle to be used is 0.5 MPa or more, and the water permeability of the blood purifier is 150 ml / Preferably, it is at least m 2 / hr / mmHg. If the burst pressure is less than 0.5 MPa, it may not be possible to detect a potential defect leading to a blood leak as described below. If the water permeability is too low, the dialysis efficiency may decrease. To increase the dialysis efficiency, the pore diameter is increased or the number of pores is increased. However, this tends to cause problems such as a decrease in membrane strength and defects.
- the porosity of the support layer portion is optimized by optimizing the pore diameter of the outer surface, and the solute permeation resistance and the membrane strength are balanced.
- the water content is preferably 2000 ml / m 2 / hrZmmHg or less.
- it is 1800 ml / m 2 Zhr / mmHg or less, further preferably 1500 ml / m 2 / hrZmm Hg or less, and still more preferably 1300 ml / m 2 / hr / mmHg or less.
- a leak test is performed in which the inside or outside of the hollow fiber membrane is pressurized with air in order to confirm defects in the hollow fiber membrane or the module. Module is defective when leak is detected by pressurized air As a product, an operation of discarding or repairing a defect is performed.
- the air pressure in this leak test is often several times the guaranteed pressure of the hemodialyzer (normally 500 mmHg).
- reducing the thickness deviation of the hollow fiber membrane bundle is effective in suppressing the occurrence of the potential defects described above.
- the burst pressure in the present invention is an index of the pressure resistance of the hollow fiber membrane bundle after the module is formed using the hollow fiber membrane. That is, the pressure when the inside of the hollow fiber membrane bundle is pressurized with gas and the pressure is gradually increased, and the hollow fiber membrane bursts without being able to withstand the internal pressure.
- the higher the burst pressure the less the cutting of the hollow fiber membrane bundle and the occurrence of pinholes during use are reduced, so 0.5 MPa or more is preferred 0.5 MPa or more is more preferred, and 0.6 MPa or more is more preferred I like it. If the burst pressure is less than 0.5MPa, it may have a potential defect.
- the burst pressure is preferably less than 2. OMPa. More preferably, it is less than 1.7 MPa, more preferably less than 1.5 MPa, even more preferably less than 1.3 MPa, particularly preferably less than 1.0 MPa.
- the thickness unevenness in the present invention is a deviation of the film thickness when 100 cross sections of the hollow fiber membrane bundle in the hollow fiber membrane bundle module are observed, and is a ratio of the maximum value to the minimum value. Show.
- the minimum thickness deviation of the 100 hollow fiber membranes is preferably 0.6 or more. In the present invention, if at least one hollow fiber membrane having a thickness unevenness of less than 0.6 is included in 100 hollow fiber membranes, the hollow fiber membrane may cause leakage during clinical use. Therefore, the thickness unevenness in the present invention represents a minimum value of 100 pieces which is equal to the average value.
- the pressure is more preferably 0.7 or more, further preferably 0.8 or more, and still more preferably 0.85 or more, since the formation of the compound is suppressed and the burst pressure is improved. If the thickness unevenness is too low, latent defects become apparent, and the burst pressure becomes low immediately, which may cause blood leakage to occur easily.
- the slit width of the nozzle serving as the discharge port of the film forming solution is preferable to make the slit width of the nozzle serving as the discharge port of the film forming solution strictly uniform.
- the spinning nozzle of the hollow fiber membrane bundle generally, a tube-in-orifice type nozzle having an annular portion for discharging a spinning solution and a core liquid discharge hole serving as a hollow forming agent inside thereof is used.
- the slit width refers to the width of the outer annular portion from which the spinning solution is discharged.
- the ratio of the maximum value to the minimum value of the slit width should be 1.00 or more and 1.11 or less, and the difference between the maximum value and the minimum value should be 10 xm or less, more preferably 7 xm or less.
- the force S is more preferably, more preferably, 5 zm or less, particularly preferably, 3 ⁇ m or less.
- the nozzle temperature is preferably 20-100 ° C. If the nozzle temperature is low, the temperature is easily affected by the room temperature, the nozzle temperature becomes unstable, and the discharge of the spinning solution may be uneven. For this reason, the nosling temperature is more preferably 30 ° C or more, further preferably 35 ° C or more, and still more preferably 40 ° C or more. In addition, if the temperature is too high, the viscosity of the spinning solution may be too low to stabilize the ejection, and the polyvinylpyrrolidone may undergo thermal degradation and decomposition. Therefore, the swelling temperature is more preferably 90 ° C or lower, further preferably 80 ° C or lower, and still more preferably 70 ° C or lower.
- a roller whose surface is mirror-finished in order to prevent the surface of the hollow fiber membrane from being scratched due to the slip of the hollow fiber membrane force S as the roller to be used.
- the surface is matte to minimize contact resistance with the hollow fiber membrane. It is preferable to use a processed one or a knurled one.
- a film in which the contact surface with the hollow fiber membrane is embossed is wound around the hollow fiber membrane. It is preferable to use a method in which the film is inserted into the module container, and after the film is inserted, only the film is extracted from the module container.
- the spinning solution is filtered using a filter having a pore size smaller than the thickness of the hollow fiber membrane bundle, and then discharged from the nozzle. Specifically, the solution is passed through a sintering filter with a pore diameter of 1050 am, which is provided while guiding the uniformly dissolved spinning solution from the dissolving tank to the nozzle.
- the filtration process may be performed at least once.However, if the filtration process is performed in several stages, decreasing the filter pore size in the later stages will increase the filtration efficiency and filter life. Les, preferred to.
- the filter preferably has a pore size of 10-45 ⁇ , more preferably 10-40 / m. If the pore size of the filter is too small, the back pressure will increase and the quantitativeness will decrease. Also, as a method for suppressing the inclusion of bubbles, it is effective to remove bubbles from the polymer solution for film formation. Depending on the viscosity of the spinning solution, static degassing or defoaming under reduced pressure can be used.
- the inside of the tank is sealed and left for 5 minutes to 30 minutes. This operation is repeated several times to perform a defoaming treatment. If the degree of decompression is too high, it is necessary to increase the number of times of defoaming, so it takes a long time to process. If the degree of pressure reduction is too low, the cost for increasing the degree of sealing of the system may increase.
- the total processing time is preferably 5 minutes to 5 hours. If the treatment time is too long, polybutylpyrrolidone may be decomposed and deteriorated due to the effect of reduced pressure. If the treatment time is too short, the defoaming effect may be insufficient.
- TMP (Pi + Po) / 2
- Pi is the dialyser inlet pressure and Po is the dialyser outlet pressure.
- the filtration flow rate was measured by changing the TMP at four points, and the water permeability (mLZhrZmmHg) was calculated from the slope of the relationship. At this time, the correlation coefficient between TMP and filtration flow rate must be 0.999 or more. TMP was measured within the range of 100 mmHg or less to reduce the pressure loss error due to the circuit. The water permeability of the hollow fiber membrane was calculated from the membrane area and the water permeability of the dialyzer.
- UFR (H) is the water permeability of the hollow fiber membrane (mL / m 2 / hr / mmHg)
- UFR (D) is the water permeability of the dialyzer (mL / hr / mmHg)
- A is the membrane area of the dialyzer ( m 2 ).
- the membrane area of the dialyzer was determined based on the inner diameter of the hollow fiber membrane.
- n is the number of hollow fiber membranes in the dialyzer
- ⁇ is the pi
- d is the inner diameter (m) of the hollow fiber membrane
- L is the effective length (m) of the hollow fiber membrane in the dialyzer.
- the dialysate side of the module loaded with about 10,000 hollow fiber membrane bundles was filled with water and plugged. Dry air or nitrogen was supplied from the blood side at room temperature, and pressurized at a rate of 0.5 MPa per minute. The pressure was increased, and the air pressure when the hollow fiber membrane was ruptured (burst) by the pressurized air and bubbles were generated in the liquid filled on the dialysate side was defined as the burst pressure.
- a cross section of 100 hollow fiber membranes was observed with a 200 ⁇ projector.
- the thickness of the cross-section of one yarn having the largest thickness difference in one visual field was measured.
- An eluate was obtained in accordance with the method defined in the dialysis-type artificial kidney device manufacturing standard, and polybulpyrrolidone in the eluate was quantified by a colorimetric method.
- the dried hollow fiber membrane module 100 ml of pure water was added to the hollow fiber membrane bundle lg and eluted at 70 ° C for 1 hour.
- the obtained eluate 2.5 ml, 0.2 mol aqueous solution of quinic acid 1.25 ml, 0.06 ml of a normal iodine aqueous solution 0.5 ml were mixed well, left at room temperature for 10 minutes, and the absorbance at 470 nm was measured. .
- the quantification was performed using a calibration curve obtained by performing measurement according to the above-described method using a standard polybulpyrrolidone.
- physiological saline was passed through the dialysate-side channel of the module at 5 OOmLZmin for 5 minutes, and then passed through the blood-side channel at 200mLZmin. After that, the solution was passed through the dialysate from the blood side for 3 minutes while being filtered at 200 mL Zmin, and then freeze-dried to obtain a dried membrane. The quantification was performed using the dried film.
- the eluate obtained by the method described in the section “Amount of polyvinylpyrrolidone” was measured for absorbance in the wavelength range of 200 to 350 nm using a spectrophotometer (U-3000, manufactured by Hitachi, Ltd.). The maximum absorbance at was determined.
- the hollow fiber membrane bundle was divided equally into 2.7 pieces each of 2.7 cm in the longitudinal direction, and the dried hollow fiber membrane bundle lg was weighed from each site and measured for all samples.
- the hollow fiber membrane bundle was divided equally into 2.7 pieces of 2.7 cm each in the longitudinal direction.
- the dried hollow fiber membrane bundle lg was weighed and measured for all samples.
- the measurement was carried out using a dry membrane obtained by treating in the same manner as in the method described in the section “Eluated amount of polyvinylpyrrolidone”.
- Bovine blood at 37 ° C to which coagulation was added and coagulation was suppressed was sent to the blood purifier at 200 mLZmin, and the blood was filtered at a rate of 20 mLZmin. At this time, the filtrate was returned to the blood to form a circulation system. After 60 minutes, the filtrate from the blood purifier was collected, and the red color caused by red blood cell leak was visually observed. In this blood leak test, the number of modules that leaked blood was examined using 30 blood purifiers in each of the examples and comparative examples.
- Stability was determined by the degree of increase in UV (220-350 nm) absorbance due to the storage.
- the hollow fiber membrane bundle was equally divided into 10 pieces in the longitudinal direction, and the degree of increase was measured for each sample, and the stability was determined by the maximum value. Those with a maximum value not exceeding 0.10 were accepted.
- the above-mentioned cross-linking treatment was stopped, stored, and evaluated.
- a kneading dissolver of the type that expresses a kneading effect by so-called planetary motion in which two frame-shaped blades rotate and revolve, is equipped with 1 part by mass of polyether sulfone (Sumika Ethecell (registered trademark) 4800P, manufactured by Sumika Chemtex). 0.144 parts by mass of polybutylpyrrolidone (Coridone (registered trademark) K90, manufactured by BASF) and 1 part by mass of dimethylacetamide (DMAc) were charged, and the mixture was stirred and kneaded for 2 hours. Subsequently, a mixed solution of 3.02 parts by mass of DMAc and 0.16 parts by mass of R ⁇ water was added over 1 hour.
- polyether sulfone Sudika Ethecell (registered trademark) 4800P, manufactured by Sumika Chemtex
- the rotation speed of the stirrer was increased and stirring was continued for another hour to dissolve uniformly.
- kneading and dissolution were performed in a nitrogen atmosphere.
- the temperature during kneading and dissolving was cooled so as not to exceed 40 ° C.
- the stirring fluid number and the stirring Reynolds number at the time of final dissolution were 1.0 and 100, respectively.
- the pressure in the system was reduced to 1500 mmHg using a vacuum pump, and then the system was immediately sealed and left for 15 minutes so that the solvent and the like did not evaporate and the composition of the film forming solution did not change. This operation was repeated three times to defoam the film forming solution.
- the inside of the system was replaced with nitrogen again and maintained at a slightly pressurized state.
- the above polyvier pyrrolidone having a hydrogen peroxide content of 130 ppm was used.
- the resulting film-forming solution was passed through a two-stage sintering filter of 30 / im and 15 / im in sequence, and then removed from the tube-in orifice nozzle heated to 75 ° C as a hollow forming agent at 1700 mmHg for 30 minutes in advance.
- the obtained bundle of wet hollow fiber membranes was introduced into a microwave irradiation type dryer having a structure in which a reflecting plate was placed in an oven and capable of uniform heating, and dried under the following conditions. 7kPa After heating the hollow fiber membrane bundle at an output of 1.5 kW for 30 minutes under reduced pressure, the microwave irradiation was stopped, and at the same time, the pressure was reduced to 1.5 kPa and maintained for 3 minutes. Subsequently, the degree of pressure reduction was returned to 7 kPa, and the hollow fiber membrane bundle was heated at a power of 0.5 kW for 10 minutes by irradiating a microwave.
- the microwave was cut to reduce the degree of pressure reduction, and the pressure was maintained at 0.7 kPa for 3 minutes.
- the degree of pressure reduction was returned to 7 kPa, and microwave irradiation was performed for 8 minutes at an output of 0.2 kW to heat the hollow fiber membrane bundle.
- the degree of vacuum was reduced to 0.5 kPa and maintained for 5 minutes to condition the hollow fiber membrane bundle and finish drying.
- the maximum temperature reached on the surface of the hollow fiber membrane bundle was 65 ° C.
- the moisture content of the hollow fiber membrane bundle before drying is 330% by mass
- the moisture content of the hollow fiber membrane bundle after the first stage is 34% by mass
- the moisture content of the hollow fiber membrane bundle after the second stage is 15% by mass. %
- the water content of the hollow fiber membrane bundle after the third stage was 1.6% by mass.
- the inner diameter of the obtained hollow fiber membrane bundle was 199 ⁇ and the film thickness was 29 xm.
- the obtained hollow fiber membrane bundle was divided equally into ten pieces each of 2.7 cm in the longitudinal direction, and a dried hollow fiber membrane bundle lg was weighed from each site, and hydrogen peroxide was quantified. Hydrogen peroxide was stable at low levels at all sites. The quantitative values are shown in Tables 1 and 2.
- a blood purifier was assembled using the thus obtained bundle of hollow fiber membranes, and a leak test was performed. As a result, no adhesion failure due to the adhesion of the hollow fiber membranes was observed.
- the blood purifier was filled with RO water, and irradiated with ⁇ -rays at an absorbed dose of 25 kGy to perform a crosslinking treatment.
- a hollow fiber membrane bundle was cut out from the blood purifier after ⁇ -ray irradiation and subjected to an elution test.
- the elution amount of PVP was 5 ppm, and the maximum amount of hydrogen peroxide was 2 ppm, which was no problem.
- the storage stability of the hollow fiber membrane bundle obtained in this example is good, and the maximum of the UV (220 to 350 nm) absorbance, which is the standard for manufacturing a dialysis-type artificial kidney device, of the hollow fiber membrane bundle after storage for one year.
- the value was 0.06, which was below the reference value of 0.10.
- the blood purifier was filled with pressurized air at a pressure of 0. IMPa, and a product that passed the leak test with a pressure drop of 3 OmmAq or less for 10 seconds was used for the subsequent tests.
- a product that passed the leak test with a pressure drop of 3 OmmAq or less for 10 seconds was used for the subsequent tests.
- the hollow fiber membrane bundle was taken out from the blood purifier and the outer surface was observed with a microscope, no defects such as scratches were observed.
- Example 1 a polybierpyrrolidone having a hydrogen peroxide content of 500 ppm was used as a raw material, the kneading and dissolving temperature was set at 85 ° C, the nitrogen supply in the raw material supply system and the dissolving tank was stopped, and the hollow fiber membrane bundle was dried.
- a hollow fiber membrane bundle was obtained in the same manner as in Example 1, except that was dried by irradiating microwaves under normal pressure. Microwave irradiation was performed at 2 kW until the water content in the hollow fiber membrane bundle reached 65% by mass, and then 0.8 kW thereafter, and dried until the water content became 0.5% by mass.
- the hollow fiber membrane bundle obtained in this comparative example can maintain the maximum value of UV (220-350 nm) absorbance of 0-10 or less, which is the standard for dialysis-type artificial kidney device production, after storage for about 8 months. lost.
- Tables 1, 2, and 3 show the results.
- Comparative Example 1 except that the Froude number and the stirring Reynolds number during dissolution of Polybierpyrrolidone were 1.7 and 260, respectively, and that the washing of the hollow fiber membrane bundle was stopped, the comparative example was changed. A hollow fiber membrane bundle and a blood purifier were obtained in the same manner as in 1. In this comparative example, the Froude number and the stirring Reynolds number of Polybierpyrrolidone at the time of dissolution were too high, so that the dissolved raw material scattered in the tank and adhered to the wall, and bubbles were trapped in the solution during dissolution. An undesirable phenomenon has occurred. Tables 1 and 2 show the characteristics of the obtained hollow fiber membrane bundle and blood purifier.
- the pressure in the system was reduced to 1700 mmHg using a vacuum pump, and then the dissolution tank was sealed and left as it was for 10 minutes so that the solvent and the like did not evaporate and the composition of the film forming solution did not change.
- This operation was repeated three times to defoam the film forming solution.
- the above polybulpy lidone one having a hydrogen peroxide content of 100 ppm was used, and the supply tank in the raw material supply system and the dissolution tank were replaced with nitrogen gas.
- the Froude number and the stirring Reynolds number at the time of dissolution were 1.1 and 120, respectively.
- the resulting film-forming solution was passed through a 15 / im, 15 ⁇ m two-stage filter, and then heated to 70 ° C.
- the treated 50% by mass 0 MAc aqueous solution was discharged at the same time as the 50 ° C aqueous solution, and after passing through a 350 mm air gap section cut off from the outside air by the spinning tube, solidified in 60 ° C water.
- the nozzle slit width of the tube-in-orifice nozzle used was 45 ⁇ m on average, 45.5 ⁇ m maximum, / J ⁇ 44.5 / im, and the ratio of the maximum and minimum slit widths was 1.02. And the draft ratio was 1.2.
- the hollow fiber membrane bundle lifted from the coagulation bath was passed through a water washing tank at 85 ° C for 45 seconds to remove the solvent and excess polybierpyrrolidone, and then wound up. After winding the same polyethylene film as in Example 1 around the bundle of about 10,000 hollow fiber membranes, the membrane was immersed and washed twice in a 40 vol% aqueous solution of isopropanol at 30 ° C. for 30 minutes.
- the obtained wet hollow fiber membrane bundle was introduced into a microwave irradiation type drier having a structure in which a reflecting plate was placed in an oven and uniform heating was performed, and dried under the following conditions. After heating the hollow fiber membrane bundle at 1.5 kW output under a reduced pressure of 7 kPa for 30 minutes, the microwave irradiation was stopped and the pressure was reduced to 1.5 kPa and maintained for 3 minutes. Next, reduce the pressure to 7 kPa After returning, the hollow fiber membrane bundle was heated by irradiation with microwaves at a power of 0.5 kW for 10 minutes, the microwaves were cut off, the degree of vacuum was reduced, and 0.7 kPa was maintained for 3 minutes.
- the degree of pressure reduction was returned to 7 kPa, and microwave irradiation was performed for 8 minutes at an output of 0.2 kW to heat the hollow fiber membrane bundle.
- the degree of vacuum was raised to 0.5 kPa and maintained for 5 minutes to condition the hollow fiber membrane bundle and finish drying.
- the maximum temperature reached on the surface of the hollow fiber membrane bundle was 65 ° C.
- the moisture content of the hollow fiber membrane bundle before drying is 315% by mass
- the moisture content of the hollow fiber membrane bundle after the first stage is 29% by mass
- the moisture content of the hollow fiber membrane bundle after the second stage is 16%. %
- the water content of the hollow fiber membrane bundle after the third stage was 2.8% by mass.
- the roller used to change the yarn path during the spinning process used a mirror-finished surface, and the fixed guide used a matte-finished surface.
- the inner diameter of the obtained hollow fiber membrane bundle is 200 zm, and the film thickness is 27 ⁇ m.
- the obtained dried hollow fiber membrane bundle was equally divided into 10 pieces of 2.7 cm each in the longitudinal direction, and the dried hollow fiber membrane bundle lg was weighed from each site, and the amount of hydrogen peroxide eluted was quantified. . The eluted amount of hydrogen peroxide was stable at a low level at all sites. The quantitative values are shown in Tables 1 and 2.
- a blood purifier was assembled using the thus obtained hollow fiber membrane bundle. As a result of the leak test, no poor bonding caused by adhesion between the hollow fiber membranes was found.
- the blood purifier was filled with RO water, and irradiated with ⁇ -rays at an absorbed dose of 25 kGy to perform a crosslinking treatment.
- a hollow fiber membrane bundle was cut out from the blood purifier after ⁇ -ray irradiation and subjected to an elution test.
- the elution amount of PVP was 6 ppm, and the maximum elution amount of hydrogen peroxide was 2 ppm, which was no problem.
- the storage stability of the hollow fiber membrane bundle obtained in this example is good, and the maximum value of UV (220_350 nm) absorbance, which is the standard for dialysis type artificial kidney device production approval, of the hollow fiber membrane bundle after storage for one year. was 0.06, which was below the standard value of 0.1.
- UV (220_350 nm) absorbance which is the standard for dialysis type artificial kidney device production approval
- the hollow fiber membrane bundle was taken out of the blood purifier and the outer surface was observed with a microscope, no defects such as scratches were observed. No blood cell leak was found in a blood leak test using bovine blood. Table 3 shows the analysis results.
- Polyethersulfone (Sumika Etacel (registered trademark) 5200P, manufactured by Sumika Chemtex Co., Ltd.) 1 6 Weight 0/0, polyvinylpyrrolidone (BASF Corp. Kollidon (R) K one 90) 5.4 Weight 0/0, dimethyl ⁇ Seto amide (DMAc) 75. 6 wt%, have the agitator of water 3%
- the mixture was charged directly into the melting tank and melted at 75 ° C. At this time, the dissolution Froude number and the stirring Reynolds number were 1.0 and 120, respectively.
- the pressure inside the system was reduced to 1 500 mmHg using a vacuum pump, and then the system was immediately sealed and left for 15 minutes so that the solvent etc.
- the mixture was discharged at the same time and passed through a dry section of 600 mm, which was cut off from the outside air by a spinning tube, and then coagulated in a DMAc aqueous solution with a concentration of 10% by mass and 60 ° C.
- the nozzle slit width of the used tube orifice nozzle is 100 ⁇ on average, the maximum l / O / im, the minimum 90 / im, the ratio of the maximum value and the minimum value of the slit width are 1.22, and the draft ratio is 2.4.
- the obtained hollow fiber membrane bundle was passed through a water washing tank at 40 ° C.
- the inner diameter of the obtained hollow fiber membrane bundle was 197 ⁇ , and the film thickness was 29 / im.
- the eluted amounts of hydrogen peroxide and polyvinylpyrrolidone in the hollow fiber membrane bundle obtained in this comparative example have a high level, and the eluted amounts of hydrogen peroxide vary greatly depending on sampling points.
- a blood purifier was assembled using the thus obtained hollow fiber membrane bundle.
- Example 2 the cross-linking treatment by ⁇ -ray irradiation was not performed.
- the amount of PVP eluted was 12 ppm
- the maximum amount of hydrogen peroxide eluted was 20 ppm.
- the hollow fiber membrane bundle obtained in this comparative example was inferior in storage stability due to the high elution amount of hydrogen peroxide.
- the hollow fiber membrane bundle obtained in this comparative example can maintain the maximum value of the UV (220-350 nm) absorbance, which is the standard for dialysis-type artificial kidney device production, below 0.10 after storage for about 3 months. I can no longer do it.
- the blood purifier was filled with pressurized air at a pressure of 0.1 IMPa, and a module having a pressure drop of 30 mmAq or less for 10 seconds was used for the test.
- a blood leak test using bovine blood 2 out of 30 modules Had a blood cell leak. It is considered that pinholes and / or tears occurred due to the small thickness deviation and the excessively large outer surface pore diameter.
- the ratio of the values was 1.03 and the draft ratio was 1.1.
- the hollow fiber membrane bundle withdrawn from the coagulation bath was passed through a water washing tank at 85 ° C for 45 seconds, and the solvent and excess polybutylpyrrolidone were used. Approximately 10,000 bundles of the hollow fiber membranes were immersed in pure water and washed with an autoclave at 121 ° C. for 1 hour. After winding the same polyethylene film as in Example 1, the container was placed in a container and replaced with nitrogen, and irradiated with ⁇ -rays at an absorbed dose of 25 kGy to perform crosslinking treatment.
- the maximum amount of hydrogen peroxide eluted in the membrane bundle was 2 ppm, followed by drying in the same manner as in Example 1.
- the surface was mirror-finished.
- the fixing guide used had a matte surface as the fixed guide.
- the hollow fiber bundle had an inner diameter of 201 zm and a thickness of 43 m.As is clear from Tables 1 and 2, the amount of eluted hydrogen peroxide was stable at a low level at all sites.
- a blood purifier was assembled. As a result of the leak test, no poor bonding caused by adhesion between the hollow fiber membranes was found. RO water was filled in the blood purifier.
- the elution amount of PVP was 7 ppm, and the maximum elution amount of hydrogen peroxide was 3 pp. m, which was no problem.
- the blood purifier was filled with pressurized air at a pressure of 0. IMPa, and a product that passed the leak test with a pressure drop of 30 mmAq or less for 10 seconds was used for the subsequent tests.
- the storage stability of the hollow fiber membrane bundle obtained in this example is good, and the maximum of the UV (220_350 nm) absorbance, which is the approval standard for the production of dialysis-type artificial kidney devices, of the hollow fiber membrane bundle after storage for one year is excellent.
- the value was 0.06, which was below the reference value of 0.1.
- Table 3 shows the analysis results.
- polysulfone Amoko Co. P- 1700 17 wt%
- polyvinyl Rupiroridon BASF Corp. Kollidon (R) K one 60) 5 mass 0/0, dimethyl ⁇ Seto amide (DMA C )
- a film-forming solution comprising 73% by mass and 5% by mass of water was prepared.
- the polyvinyl pyrrolidone used had a hydrogen peroxide content of 120 ppm.
- the resulting film-forming solution was passed through a 15 ⁇ m, 15 / im two-stage filter, and then heated to 40 ° C using a tube-in-orifice nozzle.
- the hollow fiber membrane bundle lifted from the coagulation bath was passed through a water washing tank at 85 ° C. for 45 seconds to remove the solvent and excess polybutylpyrrolidone, and then wound up. About 10,000 bundles of the hollow fiber membranes were immersed in pure water and subjected to a washing treatment at 121 ° C. for 1 hour using an auto turret.
- the wet hollow fiber membrane bundle wrapped with the film is placed on a rotary table in a drying device in a 48 ⁇ 2 stage. Set it up, irradiate it with 12 kW microwave, and reduce the pressure inside the dryer to 7 kPa. Heat treatment was performed for minutes. Subsequently, the microwave irradiation was stopped, and the pressure was reduced to lkPa, and the water was evaporated by maintaining the pressure for 3 minutes. Next, the degree of pressure reduction was returned to 7 kPa, microwave irradiation was performed, and heat treatment was performed at 3.5 kW output for 7 minutes.
- the irradiation of the microphone was stopped, and the degree of reduced pressure was reduced to 0.8 kPa and maintained for 3 minutes. Further, the pressure reduction was returned to 7 kPa, and microwave irradiation was restarted.After reheating at an output of 2.5 kW for 5 minutes, the microwave irradiation was stopped, the pressure reduction was reduced to 0.5 kPa, and drying was performed for 7 minutes. Was done. Further, the hollow fiber membrane bundle was subjected to a moisture content equalization treatment at 35 ° C. for 3 hours in a ventilation dryer.
- the moisture content of the hollow fiber membrane bundle before drying in the mouth mouth was 338% by mass
- the moisture content after the first stage was 27% by mass
- the moisture content after the second stage was 14% by mass
- after the third stage Had a moisture content of 5.5% by mass and a moisture content after completion of the ventilation drying of 1.7% by mass.
- the highest temperature of the hollow fiber membrane bundle during the drying process was 56 ° C.
- the roller used for changing the yarn path during the spinning process used a mirror-finished surface, and the fixed guide used was a matte-finished surface.
- the inner diameter of the obtained hollow fiber membrane bundle was 200 ⁇
- the film thickness was 43 / m.
- a blood purifier was assembled using the hollow fiber membrane bundle obtained in this manner. As a result of the leak test, no poor bonding caused by adhesion between the hollow fiber membranes was found.
- the blood purifier was filled with RO water, and irradiated with ⁇ -rays at an absorbed dose of 25 kGy to perform a crosslinking treatment.
- a hollow fiber membrane bundle was cut out from the blood purifier after ⁇ -ray irradiation and subjected to an elution test.
- the elution amount of PVP was 7 ppm, and the maximum elution amount of hydrogen peroxide was 2 ppm, which was no problem.
- the blood purifier was filled with pressurized air at a pressure of 0.
- the quality of the hollow fiber membrane bundle can be examined from many viewpoints.
- the hollow fiber membrane bundle is cut into 27 cm in the longitudinal direction, divided into 10 equal portions at 2.7 cm intervals, and the elution amount of hydrogen peroxide is measured at each site.
- the difference A is determined based on the maximum and minimum elution volumes.
- the average elution amount is calculated by averaging the elution amount of hydrogen peroxide at each site.
- the maximum value B of the difference between the maximum or minimum elution amount and the average elution amount shall be the degree of quality variation.
- FIG. 1 shows a state of variation in the first embodiment. In the case of Comparative Example 1, it can be similarly obtained.
- Table 2 summarizes the values calculated in this way.
- the maximum value of the hydrogen peroxide elution amount is 5 ppm or less, the dispersion of the hydrogen peroxide elution amount is suppressed, and the stability of the hollow fiber membrane bundle and the blood purifier during long-term storage is maintained. You can see that it has world significance.
- Fig. 3 shows a hollow fiber membrane bundle in which the elution amount of polybierpyrrolidone from the hollow fiber membrane bundle was suppressed to lOppm or less and the amount of hydrogen peroxide eluted from the hollow fiber membrane bundle was suppressed to 5ppm or less.
- the behavior of UV absorbance when stored for one year is shown. When the amount of hydrogen peroxide eluted was kept to 5 ppm or less, the UV absorbance was kept to 0.1 or less even after long-term storage. Therefore, it can be seen that suppressing the hydrogen peroxide content in the hollow fiber membrane bundle to 5 ppm or less significantly contributes to quality stability.
- Example 1 Example 2 Example 3 Example 4 Example 1 Example 2 Example 3 Raw material P V P
- Thickness deviation 0.7 1 0 0.90 0 0.8 2 0 8 8 0.7 0.7 1 0.7 1 0.4 1 Blood leak
- the polysulfone-based selectively permeable hollow fiber membrane bundle of the present invention has a reduced amount of hydrogen peroxide eluted, the polybutyrrolidone caused by the hydrogen peroxide when the hollow fiber membrane bundle is stored for a long period of time. Etc. are suppressed. Therefore, even after long-term storage, it is possible to maintain the maximum value of UV (220-350 nm) absorbance, which is the standard for the production of dialysis-type artificial kidney devices, at 0.10 or less. Therefore, it is suitable for a hemodialysis hollow fiber type blood purifier having high water permeability and used for treatment of chronic renal failure.
- the above hollow fiber membrane bundle is economically and stably Can be manufactured.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plasma & Fusion (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- External Artificial Organs (AREA)
- Artificial Filaments (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT05727039T ATE541638T1 (de) | 2004-03-23 | 2005-03-22 | Bündel von permselektiven hohlfasermembranen auf polysulfonbasis und herstellungsverfahren dafür |
EP05727039A EP1733784B1 (en) | 2004-03-23 | 2005-03-22 | Polysulfone-base permselective hollow fiber membrane bundle and process for producing the same |
US10/599,167 US20070187320A1 (en) | 2004-03-23 | 2005-03-22 | Polysulfone-base permselective hollow fiber membrane bundle and process for producing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-085799 | 2004-03-23 | ||
JP2004085799A JP3636199B1 (ja) | 2004-03-23 | 2004-03-23 | ポリスルホン系選択透過性中空糸膜束とその製造方法および血液浄化器 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005089918A1 true WO2005089918A1 (ja) | 2005-09-29 |
Family
ID=34464065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/005140 WO2005089918A1 (ja) | 2004-03-23 | 2005-03-22 | ポリスルホン系選択透過性中空糸膜束及びその製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070187320A1 (ja) |
EP (1) | EP1733784B1 (ja) |
JP (1) | JP3636199B1 (ja) |
AT (1) | ATE541638T1 (ja) |
WO (1) | WO2005089918A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1891999A1 (en) * | 2005-04-04 | 2008-02-27 | Toyo Boseki Kabushiki Kasisha | Blood purifier |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080000830A1 (en) * | 2004-08-10 | 2008-01-03 | Kimihiro Mabuchi | Highly Water Permeable Hollow Fiber Membrane Type Blood Purifier and Process for Manufacturing the Same |
JP4846587B2 (ja) * | 2004-08-10 | 2011-12-28 | 東洋紡績株式会社 | ポリスルホン系選択透過性中空糸膜モジュール及びその製造方法 |
JP4885437B2 (ja) * | 2004-10-15 | 2012-02-29 | 東洋紡績株式会社 | 血液浄化器および血液浄化器包装体 |
JP4731875B2 (ja) * | 2004-10-15 | 2011-07-27 | 東洋紡績株式会社 | 血液浄化器の滅菌方法および血液浄化器包装体 |
US9067178B2 (en) | 2004-12-22 | 2015-06-30 | Nipro Corporation | Blood purifier package and process for manufacturing the same |
JP4596171B2 (ja) * | 2006-04-28 | 2010-12-08 | 東洋紡績株式会社 | 血液浄化器 |
JP4876704B2 (ja) * | 2006-05-09 | 2012-02-15 | 東洋紡績株式会社 | 血液浄化器 |
US8016124B2 (en) * | 2009-04-22 | 2011-09-13 | Honeywell International Inc. | Thin film gas separation membranes |
EP2641653B1 (en) | 2012-03-23 | 2021-05-12 | Agfa-Gevaert Nv | Method for manufacturing solvent resistant polymeric membranes |
WO2013148262A1 (en) * | 2012-03-28 | 2013-10-03 | Rasirc | Method of delivering a process gas from a multi-component solution |
KR102090095B1 (ko) * | 2012-09-26 | 2020-03-17 | 도레이 카부시키가이샤 | 복합 반투막 |
US20140339164A1 (en) * | 2013-05-14 | 2014-11-20 | Pall Corporation | High throughput membrane |
FR3012049B1 (fr) * | 2013-10-17 | 2022-02-25 | Abc Membranes | Fabrication d'une membrane de filtration |
US9410191B2 (en) | 2014-05-13 | 2016-08-09 | Rasirc, Inc. | Method and system for decontaminating materials |
US10150048B2 (en) | 2014-10-23 | 2018-12-11 | Rasirc, Inc. | Method, system, and device for delivery of process gas |
JP7103223B2 (ja) * | 2016-09-16 | 2022-07-20 | 住友化学株式会社 | 熱可塑性樹脂組成物およびその成形体 |
EP4196250A1 (de) * | 2020-08-12 | 2023-06-21 | Fricke und Mallah Microwave Technology GmbH | Trocknung von filtermodulen und filtergehäusen mit einem frequenzgeführten mikrowellenprozess |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11309355A (ja) * | 1998-04-28 | 1999-11-09 | Asahi Medical Co Ltd | ポリスルホン系中空糸型血液浄化膜とその製造方法 |
JP2000300663A (ja) * | 1999-04-19 | 2000-10-31 | Toyobo Co Ltd | 選択分離膜 |
JP2003284931A (ja) * | 2002-03-27 | 2003-10-07 | Asahi Medical Co Ltd | 中空糸膜の乾燥装置 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4906375A (en) * | 1984-07-14 | 1990-03-06 | Fresenius, Ag | Asymmetrical microporous hollow fiber for hemodialysis |
US5762798A (en) * | 1991-04-12 | 1998-06-09 | Minntech Corporation | Hollow fiber membranes and method of manufacture |
US5340480A (en) * | 1992-04-29 | 1994-08-23 | Kuraray Co., Ltd. | Polysulfone-based hollow fiber membrane and process for manufacturing the same |
US6355730B1 (en) * | 1995-06-30 | 2002-03-12 | Toray Industries, Inc. | Permselective membranes and methods for their production |
ATE289219T1 (de) * | 1995-06-30 | 2005-03-15 | Toray Industries | Methode zur herstellung einer teildurchlässigen hohlfasermembran aus polysulfon |
EP0856352B1 (en) * | 1995-10-09 | 2003-07-09 | Asahi Kasei Kabushiki Kaisha | Polysulfone membrane for purifying blood |
EP2255866A1 (en) * | 1997-05-19 | 2010-12-01 | Asahi Kasei Kuraray Medical Co., Ltd. | Polysulfone type hollow fiber membrane for purifying blood and process for producing the same |
KR100289413B1 (ko) * | 1997-12-30 | 2001-05-02 | 구광시 | 폴리설폰계 중공사 막 및 그의 제조 방법 |
US6475904B2 (en) * | 1998-12-03 | 2002-11-05 | Advanced Micro Devices, Inc. | Interconnect structure with silicon containing alicyclic polymers and low-k dielectric materials and method of making same with single and dual damascene techniques |
JP3293069B2 (ja) * | 1999-05-28 | 2002-06-17 | エリー株式会社 | 被加熱物の加熱方法及びその装置 |
JP4211168B2 (ja) * | 1999-12-21 | 2009-01-21 | 東レ株式会社 | 透析器の製造方法および滅菌法 |
-
2004
- 2004-03-23 JP JP2004085799A patent/JP3636199B1/ja not_active Expired - Lifetime
-
2005
- 2005-03-22 US US10/599,167 patent/US20070187320A1/en not_active Abandoned
- 2005-03-22 AT AT05727039T patent/ATE541638T1/de active
- 2005-03-22 EP EP05727039A patent/EP1733784B1/en not_active Revoked
- 2005-03-22 WO PCT/JP2005/005140 patent/WO2005089918A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11309355A (ja) * | 1998-04-28 | 1999-11-09 | Asahi Medical Co Ltd | ポリスルホン系中空糸型血液浄化膜とその製造方法 |
JP2000300663A (ja) * | 1999-04-19 | 2000-10-31 | Toyobo Co Ltd | 選択分離膜 |
JP2003284931A (ja) * | 2002-03-27 | 2003-10-07 | Asahi Medical Co Ltd | 中空糸膜の乾燥装置 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1891999A1 (en) * | 2005-04-04 | 2008-02-27 | Toyo Boseki Kabushiki Kasisha | Blood purifier |
EP1891999A4 (en) * | 2005-04-04 | 2010-07-28 | Toyo Boseki | BLOOD PURIFIER |
Also Published As
Publication number | Publication date |
---|---|
JP2007090126A (ja) | 2007-04-12 |
ATE541638T1 (de) | 2012-02-15 |
US20070187320A1 (en) | 2007-08-16 |
EP1733784A4 (en) | 2007-04-25 |
JP3636199B1 (ja) | 2005-04-06 |
EP1733784A1 (en) | 2006-12-20 |
EP1733784B1 (en) | 2012-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005089918A1 (ja) | ポリスルホン系選択透過性中空糸膜束及びその製造方法 | |
JP3642065B1 (ja) | 選択透過性分離膜および選択透過性分離膜の製造方法 | |
US7638052B2 (en) | Polysulfone-based hollow-fiber membrane with selective permeability | |
JP3580314B1 (ja) | ポリスルホン系選択透過性中空糸膜束およびその製造方法 | |
WO2005021068A1 (ja) | 高透水性中空糸膜型血液浄化器 | |
JP4483651B2 (ja) | 血液浄化用モジュールの滅菌方法 | |
JP2013009962A (ja) | 中空糸膜型血液浄化器 | |
JP4501155B2 (ja) | ポリスルホン系選択透過性中空糸膜束の製造方法 | |
JP2006068689A (ja) | 中空糸膜束の乾燥方法 | |
JP4843993B2 (ja) | 血液浄化器 | |
JP3659256B1 (ja) | ポリスルホン系選択透過性中空糸膜束およびその乾燥方法 | |
JP2005349093A (ja) | ポリスルホン系選択透過性中空糸膜 | |
JP4748348B2 (ja) | ポリスルホン系選択透過性中空糸膜束 | |
JP5580616B2 (ja) | ポリスルホン系選択透過性中空糸膜束の乾燥方法 | |
JP4379803B2 (ja) | 中空糸膜束の乾燥方法 | |
JP4843992B2 (ja) | 血液浄化器 | |
JP2006288413A (ja) | 中空糸膜型血液浄化器 | |
JP2006068716A (ja) | 中空糸膜束の乾燥方法 | |
JP2005342415A (ja) | 高透水性中空糸膜型血液浄化器 | |
JP2005342413A (ja) | ポリスルホン系選択透過性血液浄化器 | |
JP2005342092A (ja) | ポリスルホン系選択透過性中空糸膜 | |
JP2005270631A (ja) | 選択透過性分離膜 | |
JP2005270633A (ja) | 選択透過性分離膜 | |
JP2005169377A (ja) | ポリスルホン系選択透過性中空糸膜束の製造方法 | |
JP2011156532A (ja) | ポリスルホン系選択透過性中空糸膜束およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10599167 Country of ref document: US Ref document number: 2007187320 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005727039 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005727039 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10599167 Country of ref document: US |